Development of novel tumor selective MRI contrast agents.

Spago Imaging AB

SPAGO Imaging is a Swedish biotechnology company focused on the development of novel contrast agents for early and accurate visualization of cancer with MRI.

Tumor diagnosis is still a challenge and many patients worldwide are not diagnosed early enough to allow an effective treatment. SPAGO Imaging is dedicated to enhance the possibilities for detection of small soft tissue tumors with high specificity and is developing a tumorselective contrast agent, SPAGO Pix, with unique features.

The project portfolio also includes projects within drug delivery, primarily for improved treatment of cancer.